SIRS-Lab Gmbh (SIRS-Lab) has appointed Edward Currie as executive vice-president, corporate development of the company. In this newly created role, Edward will drive partnering, licensing, companion diagnostics, and corporate business development activities at SIRS-Lab. Edward, a physician specialized in clinical microbiology and infectious disease, brings 20 years of diagnostic and pharmaceutical industry experience at Eli Lilly, F. Hoffmann-La Roche, IBM.
Most recently, Edward served as chief operating officer of Kuros BioSurgery. At Roche, as global head of disease management, Edward created the company’s first integrated Pharma-Diagnostic approach for targeted treatment and personalized medicine.
On his decision to join SIRS-Lab, Edward commented “I am very excited to be joining SIRS-Lab, a highly innovative company that I believe can make a real difference to the outcomes of patients with sepsis and life-threatening infections.”
Stefan Russwurm, chief executive officer of SIRS-Lab, stated: “We are delighted to welcome Dr. Currie here at SIRS-Lab. His highly regarded wealth of experience and an impressive track-record in the medical and diagnostic area, especially in the field of personalized medicine, will benefit us greatly in expanding our strategic partnerships.”